Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose
of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with
ADHD.